



HHS Public Access

Author manuscript

Am Heart J. Author manuscript; available in PMC 2020 December 01.

Published in final edited form as:

Am Heart J. 2020 December ; 230: 93–97. doi:10.1016/j.ahj.2020.09.015.

Cardiac safety research consortium “shock II” think tank report: Advancing practical approaches to generating evidence for the treatment of cardiogenic shock

Marc D. Samsky, MD^a, Mitchell W. Krucoff, MD^b, David A. Morrow, MD, MPH^c, William T. Abraham, MD^d, Fernando Aguel, MSE^e, Andrew D. Althouse, PhD^f, Eric Chen^g, Joaquin E. Cigarroa, MD^h, Adam D. DeVore, MD^a, Andrew Farb, MD^e, Ian C. Gilchrist, MDⁱ, Timothy D. Henry, MD^j, Judith S. Hochman, MD^k, Navin K. Kapur, MD^l, Valarie Morrow, MD^m, E. Magnus Ohman, MDⁿ, William W. O’Neill, MD^o, Ileana L Piña, MD^e, Alastair G. Proudfoot, MD, PhD^p, John S. Sapirstein, MD^e, Jonathan H. Seltzer, MD^q, Fred Senatore, MD, PhD^e, Meir Shinnar, MD, PhD^e, Charles A. Simonton, MD^r, Behnam N. Tehrani, MD^s, Holger Thiele, MD^t, Alexander G. Truesdell, MD^s, Ron Waksman, MD^u, Sunil V. Rao, MD^a

^aDuke University Medical Center, Duke Clinical Research Institute, Durham Veterans Administration, Durham, NC

^bDuke University Medical Center, Cardiovascular Devices Unit, eECG Core Laboratories, Duke Clinical Research Institute, Durham, NC

^cCardiovascular Division, Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA

^dDivision of Cardiovascular Medicine, The Ohio State University, Columbus, OH

^eU.S. Food and Drug Administration, CDRH/OPEQ/Office of Clinical Evidence and Analysis, Silver Spring, MD

^fCenter for Research on Healthcare Data Center (CRHC-DC), Center for Clinical Trials & Data Coordination (CCDC), Division of General Internal Medicine, University of Pittsburgh School of Medicine, Circulation: Cardiovascular Interventions, Pittsburgh, PA

^gAbbott, Chicago, IL

^hDivision of Cardiology, Knight Cardiovascular Institute, Oregon Health & Science University, Portland, OR

ⁱPennsylvania State University, Heart and Vascular Institute, Hershey, PA

^jThe Carl and Edyth Lindner Center for Research and Education at The Christ Hospital, The Carl and Edyth Lindner Family Distinguished Chair in Clinical Research, The Christ Hospital Health Network, Cincinnati, OH

^kNYU-HHC Clinical and Translational Science Institute, New York University School of Medicine, NYU Langone Health, New York, NY

^lThe CardioVascular Center, Tufts Medical Center Boston, MA

^mDuke Clinical Research Institute, Durham, NC

ⁿDuke Program for Advanced Coronary Disease, Department of Medicine, Duke Clinical Research Institute, Duke University Medical Center, Durham, NC

^oCenter for Structural Heart Disease, Division of Cardiology, Henry Ford Health System, Detroit, MI

^pDepartment of Perioperative Medicine, St. Bartholomew's Hospital, London, United Kingdom

^qWCG-ACI Clinical, Bala Cynwyd, PA

^rAbiomed, Danvers, MA

^sVirginia Heart, INOVA Heart and Vascular Institute, Alexandria, VA

^tHeart Center Leipzig at University of Leipzig, Department of Internal Medicine/Cardiology Leipzig, Germany, Leipzig Heart Institute, Leipzig, Germany

^uSection of Interventional Cardiology, MedStar Washington Hospital Center, Washington, DC

(See Tables I and II.)

The Cardiac Safety Research Consortium (CSRC) Think Tank “Defining the Clinical and Regulatory Landscape for Cardiogenic Shock”, held in September 2018, convened physicians, government regulators, and industry leaders to address the increasing use of mechanical circulatory support (MCS) devices for treatment of cardiogenic shock (CS) despite the absence of consistent evidence of a mortality benefit.¹ Think Tank participants identified common barriers to generating evidence including delays in CS diagnosis, variability of data collection and quality, non-uniform event definitions, variable international regulatory requirements for informed consent in emergency research, and a lack of clinical equipoise among some physicians when considering randomizing patients to MCS devices versus routine care. Other discussions focused on novel trial design options including registry-based trials, adaptive, and factorial designs as strategies to increase enrollment efficiency and maximize data interpretability.

The follow-up CSRC “Shock II” Think Tank on “Advancing Practical Approaches to Generating Evidence for the Treatment of Cardiogenic Shock” reconvened physicians, government regulators, and industry leaders on June 10, 2019, to crystallize initiatives and pragmatic solutions to these aforementioned challenges to determining optimal MCS use. At the conclusion of this Think Tank, the attendees agreed that CSRC efforts should focus ongoing Working Groups on four main themes. First, to create a network of “centers of excellence” committed to uniform and high-quality data capture and prospective clinical research collaboration and efficient approaches to informed consent for patients enrolled in cardiogenic shock studies. Second, to identify and develop in-kind and fiscal resources supporting collaborative efforts to advance evidence generation on the benefit/risk of MCS devices used in CS. Third, to develop consensus minimum core definitions for data elements critical to ongoing and future CS evidence development across case report forms, registries

and electronic health records. Finally, to consider where unmet clinical needs, practical opportunity and resources, and equipoise for randomization point to priority areas for clinical trials.

Standardizing cardiogenic shock care

“Centers of Excellence” for medical devices are frequently defined by procedural volumes. Cardiovascular procedural volumes are consistently and positively associated with improved clinical outcomes including survival.^{2–8} International practice guidelines recommend minimum procedural volumes for hospitals and operators for the maintenance of accreditation and competency.⁹ Positive association between clinical volume and improved outcomes is not limited to procedural-based care. Increased hospital volumes of heart failure, community-acquired pneumonia, and critically ill patients requiring mechanical ventilation have all been positively associated with improved outcomes.^{10–12}

As a result of these repeatedly demonstrated positive associations, regionalized systems of care have been implemented for time-critical scenarios. Transportation to level 1 trauma centers has reduced trauma-associated mortality by 15–20%.¹³ Increased use of fibrinolytic therapy and improved survival has been associated with integrated and regionalized systems of care for patients with acute ischemic stroke.^{14,15} Finally, coordination of ST elevation myocardial infarction (STEMI) care has served as the exemplar of operationalized systems of care. Emergency medical services, community hospitals, and tertiary referral centers seamlessly interact to form standardized “hub-and-spoke” STEMI networks to ensure timely reperfusion. Supported by the American Heart Association (AHA) and its Mission: Lifeline program, this system further provides quality assurance via real-time feedback and mechanisms for quality improvement via educational programs.^{8,16–21}

The consensus of Think Tank participants is that systems of care for CS should mirror that of STEMI. Ideally, CS care would be incorporated into already established hub-and-spoke STEMI networks. However, attendees generally agreed that there are several significant limitations to this approach. Not all PCI-capable hospitals are fully staffed with the multidisciplinary resources needed to care for patients with CS. These resources include 24/7 in-house intensivists, cardiac surgeons, and the allied health specialties, specifically critical care nurses and perfusionists required to deploy and manage MCS and the range of organ support devices required in many patients with shock and multiorgan failure.

In addition to developing regionalized systems of care, the concept of timely and coordinated multidisciplinary evaluation by an institutional “Shock Team” has been suggested as an approach to efficiently recognize, triage and manage CS patients.²² In practice, centralized shock triage might also help overcome critical barriers to trial enrollment. Along with performing clinical care, members of the shock team would also identify patients for clinical trials in real-time and be the point of contact for informed consent. Thus, in addition to technical or procedural capabilities, these aspects of a shock team might also be incorporated as criteria for shock “Centers of Excellence.”

Two contemporary examples of shock teams and standardized protocols for using invasive hemodynamic and biochemical metrics to identify and escalate to percutaneous MCS were presented at the Think Tank.^{23, 24} In these single-arm observational studies, compared to historical controls, standardized protocols were associated with higher survival rates among patients presenting with CS. In both examples, invasive hemodynamics and laboratory values such as lactate were predictive of outcomes, but it remains unclear which components of the protocol drove the clinical impact. Extension of the Detroit Cardiogenic Shock initiative to a nationwide network that uses protocols to assess responses to intervention demonstrates the feasibility of protocol-driven CS treatment.^{23, 24} Although encouraging, these observational studies require further validation with prospective randomized controlled trials.

Identification of research partners and resources support efficient evidence development for MCS in cardiogenic shock

The current climate of high volume MCS use, high reimbursement rates, and a need to better safety of device use was discussed as an impetus focus for rapid generation of more evidence. Furthermore, the absence of prospective randomized data was identified as an opportunity to form collaborative initiatives across industry, federal agencies, professional societies, and international stakeholders.

Ongoing international trials were discussed, including the DanGer shock²⁵ ([NCT01633502](#)), EuroShock ([NCT03813134](#)), and Extracorporeal Life Support in Cardiogenic Shock (ECLS-Shock) trials ([NCT03637205](#)). These European trials will provide much needed prospective randomized data regarding MCS device use in patients with CS associated with acute myocardial infarction. Despite interest in expanding these trials to include U.S. sites, Think Tank attendees agreed that current barriers to CS trial enrollment were problematic and that alternative strategies were both desirable and feasible.

The Cardiogenic Shock Working Group (CSWG) is a registry-based initiative with a focus on clinical CS phenotyping. CSWG investigators successfully identified clinical sub-phenotypes within Society for Cardiovascular Angiography and Interventions (SCAI) classification system using including invasive hemodynamics and MCS use which were associated with in-hospital mortality.^{26,27}

Historically, systems developed for electronic health records and the infrastructure used to conduct clinical trials operate independently, requiring redundant data collection by sites resulting in increased trial costs. Participants agreed that registry-based randomized trials would be an ideal fit for more efficient CS research.²⁸⁻³⁰ Similarly, informatics platforms incorporated into EHRs that automatically populate research protocol case-report forms extracted from clinical workflow could be a future model to optimize trial efficiency and reduce costs.^{28, 31} Additionally, ongoing registry data independent of RCTs could provide highly useful real-world practice information, temporal trends in outcomes, and improvements in performance measures.

Definitions of Cardiogenic Shock and the Academic Research Consortium: SHARC

Since the initial CSRC CS Think Tank in September 2018, multiple MCS RCTs have initiated enrollment or are planned to start.³² CS is heterogeneous in etiology and presentation, and CS outcomes are likely related to the impact of patient characteristics, disease severity at time of CS diagnosis, underlying etiology, timing of evidence-based intervention (i.e. revascularization) where appropriate, and complications of therapy.

The recently published SCAI classification system provides a practical and useful characterization of the spectrum of CS from “at-risk” to end-stage.³³ The schema was developed to simplify and standardize terminology to facilitate professional staff communication regarding a patient’s clinical status. The SCAI classification. It also could be applied to future trials to advance homogeneity of patient recruitment, poolability of data, and generalizability of outcomes. Retrospective cohort studies have shown associations between SCAI CS subgroups and clinical outcomes.^{26,27,34} However, there was agreement among think tank participants that further data are required to assess the accuracy and prognostic and clinical utility of this classification system. For example, hemodynamic criteria are not central to the SCAI schema, despite being key prognostic markers in recent and current RCTs.

The heterogeneity of CS definitions used in practice and clinical research was repeatedly discussed as a barrier to comparisons across trials, which limits the knowledge about MCS benefit/risk in CS patients. Pragmatic consensus definitions with common data elements for future clinical research were recognized as key steps to advancing the CS research landscape. Professional societies may be helpful in developing such consensus definitions. However, a unique need for MCS device evidence development requires definitions that support clinical trial processes such as adverse event adjudication and safety monitoring. The Academic Research Consortium (ARC) was established in 2006 to “create a dynamic, open-ended, transparent, collaborative forum across stakeholders, whose objective is to develop consensus definitions and nomenclature and related processes, optimized for application in pivotal clinical trials of new medical devices, and to disseminate such definitions and recommended processes into the public domain.”³⁵ Think Tank participants encouraged the creation of a shock-ARC (SHARC) initiative as a high priority for public health benefit, which would include patients, providers, industry sponsors, federal agencies, and regulators.

Key research question(s)

The purpose of the CSRC is to advance scientific knowledge on cardiac safety by facilitating pragmatic research. There was support from attendees for the creation of a working group tasked with generating a focused list of clinical questions to be discussed at the follow up CSRC Shock III meeting scheduled for February 2020. The aim of the Shock III meeting is reaching consensus on the first clinical question to be addressed in an initial pragmatic trial. The driving principles of the initiative will be an emphasis on feasibility, to showcase the capabilities of a collaborative research network including rapid identification of CS patients,

high quality standardized data collection, and novel informed consent solution(s) to create a uniquely efficient avenue for projects of interest to clinical, scientific, industry, federal and regulatory communities. Proposals included a more thorough safety analysis of temporary MCS devices, anticoagulation strategies for temporary MCS, MCS weaning algorithms, and vascular access approaches including device removal strategies.

Conclusions

The follow-up CSRC Think Tank focusing on CS “Practical Approaches to Generating Evidence for the Treatment of Cardiogenic Shock” began to crystallize a collaborative path for CS research. Four key initiatives were identified as the focus of future CSRC CS efforts. The first initiative is to establish a CS network to support and conduct research with an emphasis on reliable data collection and reporting. Second, to engage with existing CS research collaboratives and to identify potential financial and non-financial resources to support future CS research; third, to leverage the ARC and establish SHARC to create fit-for-purpose definitions to be used in CS research. Finally, to develop a set of feasible research questions that would lead to pragmatic randomized trials of interest to a broad range of CS stakeholders.

Acknowledgments

Conflicts of interest

Alexander G. Truesdell is a consultant and member of the Speakers Bureau of Abiomed Inc.

David A. Morrow reports no conflicts relevant to this work and reports grants from Anthos Therapeutics, grants and personal fees from AstraZeneca, personal fees from Bayer Pharma, grants from Daiichi Sankyo, grants from Eisai, grants from GlaxoSmithKline, personal fees from InCarda, grants from Medicines Company, grants and personal fees from Merck & Co, grants and personal fees from Novartis, grants from Pfizer, grants from Quark, grants from Regeneron, grants and personal fees from Roche Diagnostics, grants from Siemens, grants from Takeda, and grants from Zora Biosciences outside the submitted work; Dr. Morrow is also a member of the TIMI Study Group which has received institutional research grant support through Brigham and Women’s Hospital from Abbott; Amgen; Aralez; AstraZeneca; Bayer HealthCare Pharmaceuticals, Inc.; BRAHMS, Daiichi-Sankyo; Eisai; GlaxoSmithKline; Intarcia; Janssen; Med-Immune; Merck; Novartis; Pfizer; Poxel; Quark Pharmaceuticals; Regeneron; Roche; Siemens; Takeda; The Medicines Company; and Zora Biosciences.

E. Magnus Ohman mentions Chiesi (USA), Jansen Pharmaceutical, Xylocor, Cardinal Health, Milestone Pharmaceutical, Abiomed, and Cara Therapeutics.

Ian C. Gilchrist reports no conflicts relevant to this work and is a consultant for Terumo Medical, Inc.

Judith S. Hochman reports no conflicts relevant to this work; Dr. Hochman is PI for the ISCHEMIA trial for ich, in addition to support by National Heart, Lung, and Blood Institute grant, there were in-kind donations for participating sites from Abbott Vascular; Medtronic, Inc.; St. Jude Medical, Inc.; Volcano Corporation; Arbor Pharmaceuticals, LLC; AstraZeneca Pharmaceuticals, LP; Merck Sharp & Dohme Corp.; Omron Healthcare, Inc.; and Amgen Inc.; and financial donations from Arbor Pharmaceuticals LLC and AstraZeneca Pharmaceuticals LP.

Navin K. Kapur is a consultant/receives speaker honoraria from Abbott, Abiomed, Boston Scientific, Medtronic, LivaNova, Getinge, MD Start, and Precardia as well as institutional research grants from Abiomed, Boston Scientific, and MD Start.

Ron Waksman is an advisory board/board member and consultant for Abbott Vascular, Amgen, Pi-Cardia LTD, Cardioset, Medtronic, Philips (Volcano), and Boston Scientific Corp; consultant for Biosensors, Biotronik; received grant support from Abbott Vascular, AstraZeneca, Biosensors, Biotronik, Chiesi, and Boston Scientific Corp; is on the Speaker Bureau of AstraZeneca and Chiesi; and is an investor in MedAlliance.

Eric Chen is an employee of Abbott.

Adam DeVore reports research funding through his institution from the American Heart Association; Amgen; AstraZeneca; Bayer; Intra-Cellular Therapies; American Regent, Inc; the NHLBI; Novartis; and PCORI. He also provides consulting services for Amgen, AstraZeneca, Bayer, CareDx, InnaMed, LivaNova, Mardil Medical, Novartis, Procyron, scPharmaceuticals, Story Health and Zoll and has also received non-financial support from Abbott for educational activities.

William O'Neill is a consultant for Abiomed and Abbott and receives consulting fees for his services.

Charles A. Simonton is an employee of Abiomed.

Behram N. Tehrani is a consultant for Medtronic.

Alastair G. Proudfoot, Andrew D. Althouse, Fernando Aguel, Fred Senatore, Holger Thiele, Ileana Pina, John Sapirstein, Marc Samsky, Mitchell Krucoff, Sunil Rao, Timothy D. Henry, Valarie Morrow, William T. Abraham, Joaquin E. Cigarroa, Jonathan Seltzer, and Meir Shinnar all report no conflicts relevant to this work.

References

1. Samsky M, Krucoff M, Althouse AD, et al. Clinical and regulatory landscape for cardiogenic shock: A report from the Cardiac Safety Research Consortium ThinkTank on cardiogenic shock. *Am Heart J* 2019;219:1–8. [PubMed: 31707323]
2. Sollano JA, Gelijns AC, Moskowitz AJ, et al. Volume-outcome relationships in cardiovascular operations: New York State, 1990-1995. *J Thorac Cardiovasc Surg* 1999;117:419–28. discussion 428–30. [PubMed: 10047643]
3. Post PN, Kuijpers M, Ebels T, et al. The relation between volume and outcome of coronary interventions: a systematic review and meta-analysis. *Eur Heart J* 2010;31:1985–92. [PubMed: 20511324]
4. Wen HC, Tang CH, Lin HC, et al. Association between surgeon and hospital volume in coronary artery bypass graft surgery outcomes: a population-based study. *Ann Thorac Surg* 2006;81:835–42. [PubMed: 16488681]
5. Birkmeyer JD, Siewers AE, Finlayson EV, et al. Hospital volume and surgical mortality in the United States. *N Engl J Med* 2002;346: 1128–37. [PubMed: 11948273]
6. Hannan EL, Wu C, Walford G, et al. Volume-outcome relationships for percutaneous coronary interventions in the stent era. *Circulation* 2005;112:1171–9. [PubMed: 16103238]
7. Fanaroff AC, Zakrofsky P, Dai D, et al. Outcomes of PCI in relation to procedural characteristics and operator volumes in the United States. *J Am Coll Cardiol* 2017;69:2913–24. [PubMed: 28619191]
8. Canto JG, Zalenski RJ, Ornato JP, et al. Use of emergency medical services in acute myocardial infarction and subsequent quality of care. *Circulation* 2002;106:3018–23. [PubMed: 12473545]
9. Harold JG, Bass TA, Bashore TM, et al. ACCF/AHA/SCAI 2013 update of the clinical competence statement on coronary artery interventional procedures: a report of the American College of Cardiology Foundation/American Heart Association/American College of Physicians Task Force on Clinical Competence and Training (writing committee to revise the 2007 clinical competence statement on cardiac interventional procedures). *Circulation* 2013;128: 436–72. [PubMed: 23658439]
10. Kahn JM, Goss CH, Heagerty PJ, et al. Hospital volume and the outcomes of mechanical ventilation. *N Engl J Med* 2006;355: 41–50. [PubMed: 16822995]
11. Ross JS, Normand SL, Wang Y, et al. Hospital volume and 30-day mortality for three common medical conditions. *N Engl J Med* 2010;362:1110–8. [PubMed: 20335587]
12. Chen EW, Canto JG, Parsons LS, et al. Relation between hospital intra-aortic balloon counterpulsation volume and mortality in acute myocardial infarction complicated by cardiogenic shock. *Circulation* 2003;108:951–7. [PubMed: 12912817]
13. Celso B, Tepas J, Langland-Orban B, et al. A systematic review and meta-analysis comparing outcome of severely injured patients treated in trauma centers following the establishment of trauma systems. *J Trauma Acute Care Surg* 2006;60:371–8.

14. Alberts MJ, Latchaw RE, Selman WR, et al. Recommendations for comprehensive stroke centers: a consensus statement from the Brain Attack Coalition. *Stroke* 2005;36:1597–616. [PubMed: 15961715]
15. Ganesh A, Lindsay P, Fang J, et al. Integrated systems of stroke care and reduction in 30-day mortality: A retrospective analysis. *Neurology* 2016;86:898–904. [PubMed: 26850979]
16. Henry TD, Sharkey SW, Burke MN, et al. A regional system to provide timely access to percutaneous coronary intervention for ST-elevation myocardial infarction. *Circulation* 2007;116:721–8. [PubMed: 17673457]
17. Granger CB, Henry TD, Bates WE, et al. Development of systems of care for ST-elevation myocardial infarction patients: the primary percutaneous coronary intervention (ST-elevation myocardial infarction-receiving) hospital perspective. *Circulation* 2007;116: e55–9. [PubMed: 17538039]
18. Jacobs AK, Antman EM, Faxon DP, et al. Development of systems of care for ST-elevation myocardial infarction patients: executive summary. *Circulation* 2007;116:217–30. [PubMed: 17538045]
19. Jollis JG, Al-Khalidi HR, Roettig ML, et al. Regional Systems of Care Demonstration Project: American Heart Association Mission: Lifeline STEMI Systems Accelerator. *Circulation* 2016;134:365–74. [PubMed: 27482000]
20. Jollis JG, Granger CB, Henry TD, et al. Systems of care for ST-segment-elevation myocardial infarction: a report from the American Heart Association’s Mission: Lifeline. *Circ Cardiovasc Qual Outcomes* 2012;5:423–8. [PubMed: 22619274]
21. Jollis JG, Roettig ML, Aluko AO, et al. Implementation of a statewide system for coronary reperfusion for ST-segment elevation myocardial infarction. *JAMA* 2007;298:2371–80. [PubMed: 17982184]
22. Doll JA, Ohman EM, Patel MR, et al. A team-based approach to patients in cardiogenic shock. *Catheter Cardiovasc Interv* 2016;88: 424–33. [PubMed: 26526563]
23. Tehrani BN, Truesdell AG, Sherwood MW, et al. Standardized Team-Based Care for Cardiogenic Shock. *J Am Coll Cardiol* 2019;73: 1659–69. [PubMed: 30947919]
24. Basir MB, Kapur NK, Patel K, et al. Improved outcomes associated with the use of shock protocols: updates from the National Cardiogenic Shock Initiative. *Catheter Cardiovasc Interv* 2019;93: 1173–83. [PubMed: 31025538]
25. Udesen NJ, Møller JE, Lindholm MG, et al. Rationale and design of DanGer shock: Danish-German cardiogenic shock trial. *Am Heart J* 2019;214:60–8. [PubMed: 31176289]
26. Thayer K, Newman S, Swain L, et al. TCT-812 Modified SCAI Classification for Cardiogenic Shock is associated with increasing in-hospital mortality: a report from the Cardiogenic Shock Working Group Registry. *J Am Coll Cardiol* 2019;74:B795.
27. Thayer K, Newman S, Ayouty M, et al. Phenotypes of cardiogenic shock associated with increasing in-hospital mortality: a report from the National Cardiogenic Shock Working Group Registry. *Circulation* 2019;140:A15943.
28. Hess CN, Rao SV, Kong DF, et al. Embedding a randomized clinical trial into an ongoing registry infrastructure: unique opportunities for efficiency in design of the Study of Access site For Enhancement of Percutaneous Coronary Intervention for Women (SAFE-PCI for Women). *Am Heart J* 2013;166:421–8. [PubMed: 24016489]
29. Fröbert O, Lagerqvist B, Olivecrona GK, et al. Thrombus aspiration during ST-segment elevation myocardial infarction. *N Engl J Med* 2013;369:1587–97. [PubMed: 23991656]
30. Lauer MS, D’Agostino RB Sr. The randomized registry trial—the next disruptive technology in clinical research? *N Engl J Med* 2013;369: 1579. [PubMed: 23991657]
31. Rao SV, Hess CN, Barham B, et al. A registry-based randomized trial comparing radial and femoral approaches in women undergoing percutaneous coronary intervention: the SAFE-PCI for Women (Study of Access Site for Enhancement of PCI for Women) trial. *JACC Cardiovasc Interv* 2014;7:857–67. [PubMed: 25147030]
32. Thiele H, Ohman EM, de Waha-Thiele S, et al. Management of cardiogenic shock complicating myocardial infarction: an update 2019. *Eur Heart J* 2019;40:2671–83. [PubMed: 31274157]

33. Baran DA, Grines CL, Bailey S, et al. SCAI clinical expert consensus statement on the classification of cardiogenic shock: This document was endorsed by the American College of Cardiology (ACC), the American Heart Association (AHA), the Society of Critical Care Medicine (SCCM), and the Society of Thoracic Surgeons (STS) in April 2019. *Catheter Cardiovasc Interv* 2019;94:29–37. [PubMed: 31104355]
34. Jentzer JC, Baran DA, van Diepen S, et al. Admission Society for Cardiovascular Angiography and Intervention shock stage stratifies post-discharge mortality risk in cardiac intensive care unit patients. *Am Heart J* 2020;219:37–46. [PubMed: 31710843]
35. Krucoff MW, Mehran R, van Es G-A, et al. The Academic Research Consortium Governance Charter. *J Am Coll Cardiol Interv* 2011;4: 595–6.

Table I.

Cardiac Safety Research Consortium Working Groups for Cardiogenic Shock

Group name	Assignment
Shock network	Establish a cardiogenic shock network in order to conduct future research with a key emphasis on reliable data collection and reporting
Resources	Identify entities already conducting cardiogenic shock research and to identify potential financial and non-financial resources to support future research
SHARC	Create fit for purpose definitions to be used in future cardiogenic shock research
First clinical question	Develop a set of feasible research questions that would lead to pragmatic randomized trials of interest to a broad range of cardiogenic shock stakeholders

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript

Table II.

Research ideas generated during CSRC Think Tank 2.

Concept	Randomization strategy
Anticoagulation management	Cluster randomized
• Systemic vs purge/infusate algorithms	
• Dosing, target therapeutic ranges	
• Alternatives to heparin	
MCS access site	Patient or cluster randomization
Device removal strategy	Patient randomization
Weaning protocols	Cluster randomization

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript